Zarnestra Phase III Trial May Lack Sufficient Power To Show Survival Benefit

An ongoing Phase III trial of Johnson & Johnson's acute myeloid leukemia therapy Zarnestra may lack sufficient power to show a survival benefit, the FDA Oncologic Drugs Advisory Committee biostatistician suggested May 6